These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 38159908)
1. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma. Gavrielatou N; Fortis E; Spathis A; Anastasiou M; Economopoulou P; Foukas GRP; Lelegiannis IM; Rusakiewicz S; Vathiotis I; Aung TN; Tissot S; Kastrinou A; Kotsantis I; Vagia EM; Panayiotides I; Rimm DL; Coukos G; Homicsko K; Foukas P; Psyrri A Ann Oncol; 2024 Apr; 35(4):340-350. PubMed ID: 38159908 [TBL] [Abstract][Full Text] [Related]
2. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086 [TBL] [Abstract][Full Text] [Related]
3. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients. Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098 [TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab. Kuba K; Inoue H; Matsumura S; Enoki Y; Kogashiwa Y; Ebihara Y; Nakahira M; Yamazaki T; Yasuda M; Kaira K; Kagamu H; Sugasawa M Sci Rep; 2022 Dec; 12(1):22557. PubMed ID: 36581686 [TBL] [Abstract][Full Text] [Related]
6. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Okamoto I; Sato H; Tsukahara K Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271 [TBL] [Abstract][Full Text] [Related]
7. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study. Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522 [TBL] [Abstract][Full Text] [Related]
8. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review. Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179 [TBL] [Abstract][Full Text] [Related]
9. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970 [TBL] [Abstract][Full Text] [Related]
10. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181 [TBL] [Abstract][Full Text] [Related]
11. Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Serafini MS; Cavalieri S; Licitra L; Pistore F; Lenoci D; Canevari S; Airoldi M; Cossu Rocca M; Strojan P; Kuhar CG; Merlano M; Perrone F; Vingiani A; Denaro N; Perri F; Argiris A; Gurizzan C; Ghi MG; Cassano A; Allegrini G; Bossi P; De Cecco L J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290766 [TBL] [Abstract][Full Text] [Related]
12. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation. Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199 [TBL] [Abstract][Full Text] [Related]
13. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis. Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X Front Immunol; 2021; 12():645170. PubMed ID: 33897693 [TBL] [Abstract][Full Text] [Related]
14. Role of programmed death-ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma. Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A Head Neck; 2020 Nov; 42(11):3275-3281. PubMed ID: 32671898 [TBL] [Abstract][Full Text] [Related]
15. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings. Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528 [TBL] [Abstract][Full Text] [Related]
16. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123 [TBL] [Abstract][Full Text] [Related]
17. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547 [TBL] [Abstract][Full Text] [Related]
18. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients. Foy JP; Karabajakian A; Ortiz-Cuaran S; Boussageon M; Michon L; Bouaoud J; Fekiri D; Robert M; Baffert KA; Hervé G; Quilhot P; Attignon V; Girod A; Chaine A; Benassarou M; Zrounba P; Caux C; Ghiringhelli F; Lantuejoul S; Crozes C; Brochériou I; Pérol M; Fayette J; Bertolus C; Saintigny P Eur J Cancer; 2022 Oct; 174():287-298. PubMed ID: 36038492 [TBL] [Abstract][Full Text] [Related]
19. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697 [TBL] [Abstract][Full Text] [Related]
20. PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma. Su NW; Dai SH; Hsu K; Chang KM; Ko CC; Kao CW; Chang YF; Chen CG Cancer Immunol Immunother; 2024 Jan; 73(1):3. PubMed ID: 38175307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]